ARVNArvinas Inc.Running, no new patients
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
KRAS G12D Mutation · Advanced Solid Cancer
1Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.4
5 insiders sold shares within a month
Since May 21, 2026 · was worth 10, fading over time
Worry score1
Score over time
- Stage
- Phase 1/2
- Patients
- 76 (final count)
- Started
- May 29, 2025
- Main results expected
- Nov 30, 2026
- Fully finished
- Nov 30, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part A (Phase 1): Number of dose-limiting toxicities (DLTs) of ARV-806
Measured over: 28 days from first ARV-806 administration
Part A (Phase 1): Number of participants with AEs
Measured over: From the study baseline to at least 28 days after last dose of ARV-806
Part B (Phase 2): Overall Response Rate (ORR)
Measured over: Approximately 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 1.4, since 2026-05-21, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07023731 · record last updated 2026-09-16 · checked 2026-11-09 15:47 UTC